Cargando…

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

BACKGROUND: Epigenetic mechanisms have important roles in the tumour escape from immune responses, such as in MHC class I downregulation or altered expression of other components involved in antigen presentation. Chemotherapy with DNA methyltransferase inhibitors (DNMTi) can thus influence the tumou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Šímová, J, Polláková, V, Indrová, M, Mikyšková, R, Bieblová, J, Štěpánek, I, Bubeník, J, Reiniš, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242529/ https://www.ncbi.nlm.nih.gov/pubmed/22015556 http://dx.doi.org/10.1038/bjc.2011.428

Ejemplares similares

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines
por: Simova, Jana, et al.
Publicado: (2016)

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy
por: MIKYŠKOVÁ, ROMANA, et al.
Publicado: (2015)

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes
por: Vlková, Veronika, et al.
Publicado: (2014)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
por: Kailayangiri, S, et al.
Publicado: (2012)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

Distinct phenotypes and ‘bystander’ effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines
por: Sapega, Olena, et al.
Publicado: (2018)

Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma
por: Oguejiofor, K, et al.
Publicado: (2015)

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
por: Daayana, S, et al.
Publicado: (2010)

Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16
por: Šmahel, M, et al.
Publicado: (2001)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide
por: Conway, Gillian E, et al.
Publicado: (2016)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
por: Arts, J, et al.
Publicado: (2007)

Increased expression of class III β-tubulin in castration-resistant human prostate cancer
por: Terry, S, et al.
Publicado: (2009)

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
por: Griffiths, R W, et al.
Publicado: (2005)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells
por: Chakraborty, S, et al.
Publicado: (2011)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_7gff6lo7en4fmuali86o171c29